BioNTech records loss of 190 mln euros in Q2 as covid vaccine demand wanes
BERLIN, Aug. 7 (Xinhua) -- German developer and manufacturer of active immunotherapies BioNTech on Monday posted a loss of 190 million euros (209 million U.S. dollars) in the second quarter of 2023 as demand for its COVID-19 vaccine waned.
In the same period last year, the company made a profit of 1.67 billion euros. Looking ahead, BioNTech still anticipates "seasonal demand" and plans to release an adjusted COV